Testosterone Gel Makers Brace For REMS, Black Box Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Risks of skin contact with children and women were known, but severity of adverse events took the field by surprise.
You may also be interested in...
Beyond Individual Patients: FDA Emphasizes Public Health Role In Certain Benefit-Risk Decisions
US FDA’s new draft guidance on benefit-risk assessments for new drugs highlights cases where it can take into account broader public health implications than just the pros and cons calculus for the patients described in a drug's label. While not a new policy perse, it is one the agency seems to have only grudgingly employed in the past.
Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1
FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.
Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1
FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.